Back to top
more

Pfizer (PFE)

(Delayed Data from NYSE)

$29.09 USD

29.09
25,001,151

+0.12 (0.41%)

Updated Sep 27, 2024 04:02 PM ET

After-Market: $29.09 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value F Growth D Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 18% (45 out of 251)

Industry: Large Cap Pharmaceuticals

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Is a Beat Likely for Moderna (MRNA) This Earnings Season?

by Zacks Equity Research

Investors are likely to focus on any updated outlook for Moderna's (MRNA) authorized coronavirus vaccine, on the second-quarter earrings call.

Corcept's (CORT) Q2 Earnings Beat Estimates, Revenues Rise Y/Y

by Zacks Equity Research

Corcept (CORT) beats on both earnings and revenues in the second quarter of 2021. The company maintains the revenue guidance for 2021.

Kinjel Shah headshot

Pharma Stock Roundup: Q2 Earnings of MRK, PFE & Others, FDA Approvals for GSK, ABBV

by Kinjel Shah

Pfizer (PFE), Merck (MRK) and others announce Q2 results. FDA approves AbbVie's (ABBV) new antibiotic injection and expands use of Merck's Keytruda and Glaxo's Shingrix and Nucala.

Sanghamitra Saha headshot

Pharma & Healthcare ETFs at a One-Year High: Here's Why

by Sanghamitra Saha

Upbeat earnings, COVID-19-related sales, compelling valuation and lucrative dividend prospects are boosting pharma and healthcare ETFs.

Glaxo's (GSK) Q2 Earnings Beat, Revenues on Recovery Track

by Zacks Equity Research

Glaxo's (GSK) revenues benefit from recovery in sales of products across all segments and additional revenues from the supply of pandemic adjuvant to partners.

Stock Market News for Jul 29, 2021

by Zacks Equity Research

U.S. stock markets closed mixed on Wednesday following the Fed's decision to keep interest rate near zero.

Bristol-Myers' (BMY) Q2 Earnings Beat, Opdivo Sales Grow

by Zacks Equity Research

Bristol-Myers (BMY) beats on earnings and sales in the second quarter as Opdivo sales revive.

Earnings Data Deluge

by Zacks Equity Research

Earnings Data Deluge.

Mark Vickery headshot

Trade Numbers Sink Near Record, Q2 Earnings Beats for PFE, BA & MCD

by Mark Vickery

Boeing (BA) posted a surprise profit in Q2, and shares are up over 5% in pre-market trading as a result.

Pfizer (PFE) Q2 Earnings Beat, View Up on COVID-19 Vaccine

by Zacks Equity Research

Pfizer (PFE) beats second-quarter estimates for earnings and sales. It lifts its guidance for 2021.

Zacks Earnings ESP: A Better Way to Find Earnings Surprises for Medical

by Zacks Equity Research

Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.

Pfizer (PFE) Q2 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

Pfizer (PFE) delivered earnings and revenue surprises of 10.31% and 8.21%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Why Earnings Season Could Be Great for Pfizer (PFE)

by Zacks Equity Research

Pfizer (PFE) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Is a Beat Likely for AbbVie (ABBV) This Earnings Season?

by Zacks Equity Research

AbbVie's (ABBV) second-quarter results are expected to reflect the impact of strong demand for new drugs. Investors are likely to focus on any update related to guidance.

Gilead (GILD) to Report Q2 Earnings: What's in the Cards?

by Zacks Equity Research

Investors will focus on the HIV franchise's performance and Veklury sales when Gilead (GILD) reports second-quarter 2021 results.

Drug/Biotech Stock Earnings on Jul 28: PFE, GSK, BMY, BMRN & TLRY

by Zacks Equity Research

Let us take a look at five drug/biotech companies - PFE, GSK, BMY, BMRN and TLRY - which are gearing up for their earnings release.

Is a Beat in Store for Bristol-Myers (BMY) in Q2 Earnings?

by Zacks Equity Research

Investors will focus on regular top and bottom-line numbers along with key pipeline updates when Bristol-Myers (BMY) reports second-quarter 2021 results.

Merck (MRK) to Report Q2 Earnings: What's in the Cards?

by Zacks Equity Research

Investor focus is likely to be on the sales numbers of Merck's (MRK) blockbuster oncology medicine, Keytruda.

Vaxart (VXRT) to Report Q2 Earnings: What's in the Cards?

by Zacks Equity Research

On Vaxart's (VXRT) second-quarter earnings call, investors are set to mainly focus on updates on the company's progress with oral vaccine candidates for COVID-19 and Norovirus.

What's in the Cards for AstraZeneca (AZN) in Q2 Earnings?

by Zacks Equity Research

AstraZeneca's (AZN) second-quarter results are expected to reflect the impact of strong demand for new drugs. Investors are likely to focus on an updated guidance after Alexion acquisition.

Arvinas (ARVN), Pfizer Team up for Breast Cancer Therapy

by Zacks Equity Research

Arvinas (ARVN) collaborates with Pfizer for its investigational breast cancer candidate, ARV-471. Pfizer is also set to acquire an equity stake in Arvinas. The stock rises 9% post the announcement.

Will Pfizer (PFE) Beat Expectations This Earnings Season?

by Zacks Equity Research

Higher sales of Pfizer's (PFE) key brands, Eliquis, Xeljanz, and Inlyta, and revenues from COVID-19 vaccine are likely to have driven sales in the second quarter.

Glaxo (GSK) to Report Q2 Earnings: What's in the Cards?

by Zacks Equity Research

Glaxo's (GSK) newer respiratory and HIV drugs are likely to have driven second-quarter sales. However, sales of vaccines are likely to have been hurt by COVID-19 vaccine prioritization.

Kinjel Shah headshot

Pharma Stock Roundup: JNJ, NVS Q2 Earnings, PFE, ABBV, LLY & MRK FDA Updates

by Kinjel Shah

J&J (JNJ) and Novartis (NVS) announce Q2 results. FDA delays decisions on JAK inhibitor drugs of Lilly (LLY), AbbVie (ABBV) and Pfizer (PFE) for eczema indication.

Will Teladoc (TDOC) Q2 Earnings Show Weak Telehealth Demand?

by Zacks Equity Research

Teladoc's (TDOC) Q2 results are likely to reflect a rise in revenues but overall tepid demand as patients started visiting doctors' clinics for in-person checkups.